GenomeWeb just published this article in their latest issue. It highlights our collaboration with Toronto’s Sunnybrook Research Institute to clinically validate our ONETest Rapid product that assays infectious diseases.
It goes on to feature our new Series A funding round. Any monies raised will go to support additional clinical studies to validate our syndromic ONETest products for sepsis and nosocomial acquired infections.
Unfortunately, it’s behind GenomeWeb’s paywall but we’re excited to alert you to this news! Press like this is great for us! Please share the link!
We are pleased to share the news that Fusion Genomics has received a $1 million award to conduct a study evaluating our comprehensive, novel ONETest PathoGenome assay for the detection of pathogens associated with respiratory tract infections (RTIs). Due in great part to limitations associated with current diagnostic tests, RTIs are a leading cause of morbidity, mortality, and hospitalizations globally. Faster identification and diagnosis of pathogens responsible for these infections could help reduce their tremendous burden on patients and hospitals.
We are honored by CQDM’s decision to include the ONETest RTI assay among its prestigious portfolio of funded programs. The prospective clinical study, which we will conduct in partnership with Sunnybrook Research Institute, could help to transform the diagnosis and treatment of RTIs.
For more information, click here to read the news release we distributed this morning, and please don’t hesitate to contact us if you have any questions regarding this exciting new project.
As the key organizer of the summit, C2CAN is a collaborative platform between SFU VentureLabsⓇ, China Canada Cleantech Innovation Centre (CCCIC), Tsinghua Holdings, and Hanhai Holdings. Its mission is to connect technology companies with the resources necessary to scale and succeed in China and Canada.
Through its new Canada China Innovation Bridge program (C2 iBridge), C2CAN aims to further its mission to promote cross-border collaboration in science and technology innovation between Canada and China.
C2 Innovation & Investment Bridge (C2 iBridge) is a C2CAN program that focuses exclusively on events that support the C2CAN mission.
FUSION GENOMICSCorporation is a molecular diagnostic company that develops clinical assays using next-generation sequencing technologies to characterize infectious disease agents of clinical and global importance. We are looking to hire a full-timePostdoctoral Fellow to join our team in an exciting and highly dynamic start-up environment.
FUSION GENOMICS is looking for a passionate, self driven, team player to join our team.
The position will involve working directly with the upper management to write technical documents, grants, and white papers. The job will involve in depth literature review, review of next generation sequencing data, and writing of technical and white papers to be used internally, distributed to collaborators, scientific conferences, and marketing.
The successful candidate has demonstrable experience in:
creating technical documents
creating white papers
The successful candidate requires comprehensive knowledge of:
Next Generation Sequencing
Infectious Disease Biology
Completed your PhD within the last 2 years
A canadian citizen, permanent resident, or international student
How to Apply
Please submit a cover letter and your CV featuring your top 3-5 publications to: email@example.com
Location: Vancouver, Lower Mainland
FUSION GENOMICS is located at SFU Venture Labs in Discovery Park on the main SFU campus in Burnaby, BC. We offer a highly competitive compensation package that includes a base salary and health benefits. Combine that with the opportunity and challenge to develop your career and to experience FUSION as a great fit for your next career move.
Fusion Genomics is looking to hire a full-time Senior Computational Biologist to join our software development team in an exciting and highly dynamic start-up environment.
The successful applicant will participate in developing, improving and maintaining bioinformatics tools that will advance our NGS assays. This will entail the analysis and interpretation of assay results from genomic clinical datasets, developing genomic models using machine learning, and providing analysis support to our colleagues and external collaborators. The successful candidate will work independently but will interact with software programmers, database developers, other bioinformaticians and laboratory personnel. This role requires a broad knowledge of bioinformatics statistics, and programming, paired with effective communication skills, meticulous attention to detail in analysis, and timeliness.
Develop and maintain bioinformatics pipelines to analyze genomic data from infectious diseases.
Provide bioinformatics support for clinical/analytical validation of genomic assays.
Produce thorough but concise written documentation of algorithms, validations, SOPs, and other processes and procedures as required.
Perform literature search, testing and validation of new data analysis software / techniques.
Foster effective and collaborative working relationships with fellow employees, management and external partners.
Support and assist colleagues in data preparation and bioinformatics analysis.
Contribute to manuscript drafting for peer-reviewed journals.
PhD or MSc from a quantitative field with strong programming experience (bioinformatics, computational biology, data science, statistics, applied math, computer science, or an allied field). At least 2 years of recent related experience.
Experience in implementing and validating bioinformatics methods.
Experience working with NGS analysis tools such as SAMtools, BWA, and Bowtie2.
Proficiency in working in a Unix environment, including experience with shell scripting and common command-line tools.
Working knowledge of distributed version control systems, such as GIT.
Proven expertise with Python, C/C++ and or other similar high-level languages.
Demonstrated ability to effectively communicate in spoken and written English.
Demonstrated ability to efficiently organize work assignments and establish priorities.
Proven interpersonal skills with the ability to work collaboratively as a member of cross-functional team.
Background in molecular biology and/or infectious diseases a plus.
Experienced in the application of machine learning algorithms a plus.
Location: Vancouver, Lower Mainland
FUSIONGENOMICS is located at SFU Venture Labs in Discovery Park on the main SFU campus in Burnaby, BC. We offer a highly competitive compensation package that includes a base salary and health benefits. Combine that with the opportunity and challenge to develop your career and we hope you will see FUSION as a great fit for your next career move.
The Ready to Rocket list comprises companies that show the “greatest potential for revenue growth.” Of the 5 category winners chosen this year, Fusion Genomics was the winner in the Life Sciences category. We are pleased to be awarded this honour! Although we are glad to see us mentioned in this article published by Vancouver’s own Georgia Straight, we do wish they had done a better job of describing what we do; supplying a simple test for diagnosing difficult-to-identify diseases using modern Next Generation Sequencing technology and our proprietary bioinformatics database and platform!
“Manitoba is at the heart of a region that is perfectly positioned to build a strong infrastructure for research and discovery in clean technologies,” says Dr. Simon Potter, Director of Manitoba at Genome Prairie. “We are proud to partner with Fusion Genomics to build the Genome360 program and create an innovative platform to advance genomics tools used for commercialization opportunities in clean technology and contribute to the bioeconomy.”
“It is an exciting and historic time for innovation in Canada. The Digital Technology Supercluster is a generational opportunity – one that holds significant promise for companies in BC and across Canada,” says Bill Tam, Co-Chair of Canada’s Digital Technology Supercluster consortium. “Now the important work begins. As a collective, we’ll apply data and use technology in new ways, such as mixed reality, which can digitally transform companies, solve industry problems and advance economic opportunities throughout BC, Canada and the world.”